Project Grant R01HL176659
Award Date 8/21/25
Completion Date 5/31/30
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
- This federal Project Grant award for $806,901.00 from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of oxidation-specific IgA antibodies in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The research, conducted by the University of Virginia, aims to elucidate the link between B cells, IgA, and lung fibrosis in IPF, with the goal of providing insight into disease mechanisms and identifying...
- This federal Project Grant award of $718,002 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to validate and expand on the discovery of unique inflammatory and hypoinflammatory endotypes within idiopathic pulmonary fibrosis (IPF) lung tissue and microenvironment. The research, conducted by the University of Kansas Medical Center Research Institute, Inc. (KUMCRI), will perform proteomic analysis on IPF bronchoalveolar lavage fluid and lung...
- This federal Project Grant award of $722,584 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of the desmosome-keratin intermediate filament network in lung epithelial injury, repair, and regeneration. The research aims to explore how dysfunction or loss of this network may contribute to idiopathic pulmonary fibrosis (IPF). The award was made to Tulane University, a private research institution with expertise in...
- This $386,756 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a research project to develop an exosomic signature for rapidly progressive idiopathic pulmonary fibrosis (IPF). The principal investigator, Dr. Christina Eckhardt, will leverage existing IPF patient cohorts and data to identify extracellular vesicle-associated microRNAs that can quantify and predict the risk of accelerated IPF...
- This federal Project Grant award of $248,999.00 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Virginia Commonwealth University (VCU) to support research on the role of the mechanoreceptor Piezo2 in regulating cellular metabolism and driving the progression of idiopathic pulmonary fibrosis (IPF). The project aims to characterize how Piezo2 mediates metabolic adaptations in lung fibroblasts in response to increased matrix...
- The federal Project Grant award of $726,452 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to model intra- and inter-cellular networks involved in TRPC6-dependent cardiac fibrosis. The award aims to leverage computational methods and multi-scale experiments to better understand how TRPC6 signaling drives myofibroblast transformation and fibrosis in response to cardiac and dermal wounds. The research will be conducted by the...
- This $695,403.00 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop therapeutic approaches to improve lung microvascular integrity and inhibit the progression of pulmonary fibrosis. The key proposed activities include: Evaluating whether restoring microvascular integrity through nanoparticle gene therapy can inhibit lung fibrogenesis. Determining if transplantation of FOXF1+CKIT+ endothelial progenitor cells can...
- This federal Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,752 to Duke University to investigate the mechanisms of lung fibrosis. The research aims to evaluate epithelial cell-fibroblast interactions contributing to fibroblast activation through the CTHRC1-TGFβ signaling pathway, in the context of bronchiolitis obliterans and idiopathic pulmonary fibrosis. The 2-year project leverages Duke's...
- This Project Grant award of $786,147.00 from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of hypoxia-induced lactate generation and shuttling in promoting pro-fibrotic phenotypes in lung fibroblasts. The research aims to elucidate the mechanistic links between hypoxia, aberrant lactate metabolism, and the pathobiology of progressive fibrotic lung disease, such as idiopathic pulmonary fibrosis (IPF). The...
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...